Rigel Pharmaceuticals Releases New Findings on R289 for Lower-Risk MDS at ASH 2025 At the 67th ASH Annual Meeting, Rigel Pharmaceuticals presents significant updates regarding R289, a promising treatment for lower-risk MDS.

Rigel Pharmaceuticals Releases New Findings on R289 for Lower-Risk MDS at ASH 2025 #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #MDS

Rigel Pharmaceuticals Announces Robust Q3 2025 Financial Results and Strategic Outlook In the third quarter of 2025, Rigel Pharmaceuticals reported impressive financial results, showcasing significant revenue growth and a strong business outlook.

Rigel Pharmaceuticals Announces Robust Q3 2025 Financial Results and Strategic Outlook #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #TAVALISSE

Rigel Pharmaceuticals to Present Key Data at ASH Annual Meeting 2025 Focused on Innovative Hematologic Therapies Rigel Pharmaceuticals is set to showcase vital data at the 67th ASH Annual Meeting, emphasizing breakthroughs in treating hematologic disorders including AML and MDS.

Rigel Pharmaceuticals to Present Key Data at ASH Annual Meeting 2025 Focused on Innovative Hematologic Therapies #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #mIDH1_AML

Rigel Pharmaceuticals Enrolls First Patient in R289 Expansion Study for Lower-Risk MDS Rigel Pharmaceuticals announces the enrollment of its first patient in a pivotal Phase 1b study expansion of R289, targeting lower-risk MDS treatment.

Rigel Pharmaceuticals Enrolls First Patient in R289 Expansion Study for Lower-Risk MDS #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #MDS

Rigel Pharmaceuticals Reports Impressive First Quarter Performance and Strategic Updates In its first quarter of 2025, Rigel Pharmaceuticals achieved approximately $53.3 million in revenue, marking a significant increase and promising growth in clinical development.

Rigel Pharmaceuticals Reports Impressive First Quarter Performance and Strategic Updates #USA #South_San_Francisco #Rigel_Pharmaceuticals #R289 #TAVALISSE

Rigel Pharmaceuticals Achieves FDA Orphan Drug Designation for R289 in Treating MDS Rigel Pharmaceuticals announces FDA's Orphan Drug designation for R289, aimed at treating myelodysplastic syndromes, marking a significant step forward in medical advancements.

Rigel Pharmaceuticals Achieves FDA Orphan Drug Designation for R289 in Treating MDS #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #MDS

Rigel Pharmaceuticals Presents Promising Phase 1b Study Results of R289 for Lower-Risk MDS at ASH 2024 Rigel Pharmaceuticals has unveiled initial findings from its ongoing Phase 1b study of R289 for lower-risk MDS, highlighting safety and efficacy at the ASH 2024 conference.

Rigel Pharmaceuticals Presents Promising Phase 1b Study Results of R289 for Lower-Risk MDS at ASH 2024 #United_States #San_Diego #Rigel_Pharmaceuticals #R289 #ASH_2024

Rigel Pharmaceuticals Receives FDA Fast Track Designation for R289 in Treating Lower-Risk MDS Rigel Pharmaceuticals announces R289's Fast Track designation by the FDA for patients with lower-risk myelodysplastic syndrome needing treatment, targeting inflammatory pathways.

Rigel Pharmaceuticals Receives FDA Fast Track Designation for R289 in Treating Lower-Risk MDS #United_States #South_San_Francisco #Rigel_Pharmaceuticals #R289 #MDS